Implications from hypertension outcome trials for the management of patients with hypertension and diabetes

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 4, 2003, Pages 245-251

  Brown, Morris J ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Beta blocker; Calcium channel blocker; Diabetes; Diuretic; Guidelines; Hypertension; Outcome trial

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COAMILOZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; NIFEDIPINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ALGORITHM; ANKLE EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DRUG PREFERENCE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOKALEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0042878588     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030040201     Document Type: Review

References (32)

1. Brown MJ, Castaigne A, De Leeuw PW et al. Influence of diabetes and type of hypertension on the response to antihypertensive treatment. Hypertension 2000;35:1038-42.
2. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50:272-98.
3. Brown MJ. What does STOP-2 tell us about management of hypertension? (Correspondence on STOP-2). Lancet 2000;355:653-4.
4. Sever PS, Dahlof B, Poulter NR et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001;19:1139-47.
5. Dahlof B, Devereux RB, Kjeldsen SE et al. The Losartan Intervention For Endpoint Reduction in Hypertension Study. Lancet 2002;359:995-1003.
6. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.
7. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
8. Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6.
9. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
10. Hansson L, Zanchetti A. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-62.
11. Ramsay LE, Williams B, Johnston GD et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319:630-5.
12. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999;100:354-60.
13. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
14. Sever P. Abandoning diastole. BMJ 1999;318:1773.
15. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with once-daily calcium channel blockade or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-42.
16. Cockcroft JR, Brown MJ. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet 2002;359:2202; discussion 2203-4.
17. Kjeldsen SE, Dahlof B, Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8.
18. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
19. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
20. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870-8.
21. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001;103:2579-84.
22. Millar JA, Lever AF. Implications of pulse pressure as a predictor of cardiac risk in patients with hypertension. Hypertension 2000;36:907-11.
23. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994;128:1177-83.
24. Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990;15(suppl 5):S46-S52.
25. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415-20.
26. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results: from the health survey for England 1994. J Hypertens 1998;16:747-52.
27. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet 1997;349:454-7.
28. Geller DS, Farhi A, Pinkerton N et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289:119-23.
29. Hansson JH, Nelson-WC, Suzuki H et al. Hypertension caused by a truncated epithelial sodium channel g subunit: genetic heterogeneity of Liddle syndrome. Nature Genet 1995;11:76-82.
30. Shimkets RA, Warnock DG, Bositis CM et al. Liddle's syndrome: heritable human hypertension caused by mutations in the b-subunit of the epithelial sodium channel. Cell 1994;79:407-14.
31. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. Embo J 1999;18:3024-33.
32. Lang F, Cohen P. Regulation and physiological roles of serum- and glucocorticoid-induced protein kinase isoforms. Sci STKE 2001;2001(108): RE17.